🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT07201909
Recruiting Not applicable

CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?

NCT07201909 · tracked via the Priya Life Science UK tracker
Sponsor
Myota GmbH
Phase
Not applicable
Started
2025-10-02
Last updated
2026-03-13

Condition(s) studied

Stress

Investigational drug(s) / intervention(s)

Prebiotic fibre blendMaltodextrin powder

Prebiotic fibre blend: A blend of prebiotic fibres in a powdered supplement form.

Maltodextrin powder: Maltodextrin powder

Study summary

This clinical trial will investigate whether a powdered prebiotic fibre blend can improve perceived stress levels in healthy adults with mild-severe stress levels.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-50 years of age * Capacity to give informed consent to participate in the study * Able to comply with study requirements and visits * Meet the range required for mild-severe stress levels (as assessed by DASS-42 stress subscale) * Normal or corrected to normal vision and/or hearing Exclusion Criteria: * Current smoker * Having food allergies and/or intolerances * Diagnosis of Type 1 or 2 diabetes or cardiovascular disease or psychiatric or neurological conditions (e.g. schizophrenia, dementia) including eating disorders * Current or previous diagnosis of depression in past 6 months * Receiving medications that lower cholesterol, blood pressure, blood glucose levels, or improve insulin sensitivity * Receiving antidepressant or anti-anxiety medications or treatments * Receiving hormonal birth control * Perimenopause or menopause * Pregnancy, lactation, or an intent to become pregnant during the course of the study * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Major change in dietary intake in past month (e.g. excluding whole food groups) * Currently consuming daily prebiotic or probiotic supplements * Prior use (\< 6 months) of any blood glucose or cholesterol lowering medication * Any significant GI condition affecting GI absorption including (but not limited to) inflammatory bowel disease, weight loss surgery, irritable bowel disease. * End stage renal disease * Active cancer, or treatment for any cancer, in last 3 years * Consuming more than 20g of fibre a day as assessed by the 18-item FiberScreen

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CALM Study Site London United Kingdom Recruiting

More Myota GmbH trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07201909 on ClinicalTrials.gov ↗ ← All trials in the UK